Chronic Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Pain Market Outlook

Thelansis’s “Chronic Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Pain Overview

Chronic pain is a common, complex, and distressing problem that significantly impacts society and individuals. It commonly arises as a consequence of injury or disease. Many pain categories and types exist, encompassing neuropathic, nociceptive, musculoskeletal, inflammatory, psychogenic, and mechanical pain. Risk factors have been classified into "modifiable" and "non-modifiable." The primary clinical risk factor for chronic pain development is the coexistence of acute or chronic pain at other bodily sites. The likelihood of chronic pain increases in proportion to the severity and number of these sites. Painful stimuli prompt alterations in brain chemistry that predispose individuals to chronic pain. This heightened susceptibility can manifest within days of continuous exposure to painful stimuli and persist for up to a year after pain resolution. Both having multiple causes of chronic pain and enduring pain for extended periods are associated with diminished quality of life. The differential diagnosis for generalized chronic pain encompasses patients experiencing allodynia due to chronic opioid use and those afflicted with major depressive disorder, as well as individuals with other psychiatric or sleep disorders like insomnia. Pharmacological therapies for chronic pain involve nonopioid analgesics such as nonsteroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin. Additionally, medications like tramadol, opioids, antiepileptic drugs (e.g., gabapentin or pregabalin) are employed. Moreover, antidepressants such as tricyclic antidepressants and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), topical analgesics, muscle relaxants, N-methyl-D-aspartate (NMDA) receptor antagonists, and alpha-2 adrenergic agonists are utilized as pharmacological interventions.

• In the USA, an estimated 20.9% of U.S. adults experienced chronic pain,the estimated prevalence of high-impact chronic pain (6.9%). Further, the age-adjusted prevalence of high-impact chronic pain in was 6.4%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: